EAM
JANX icon

Exome Asset Management’s Janux Therapeutics JANX Stock Holding History

Exome Asset Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-40,123
Closed -$2.15M – 69
2024
Q4 		$2.15M Buy
+40,123
New +$2.12M 1.61% 25

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Exome Asset Management's JANX Position: Q1 2025 in Review

Exome Asset Management sold out of Janux Therapeutics (JANX) in Q1 2025, closing a stake of 40,123 shares — an estimated $2.15M sold.

Exome Asset Management first reported a position in JANX in Q4 2024 and held it in 1 quarter. The position peaked at $2.15M in Q4 2024. 181 funds tracked by Wall St. Rank hold JANX as of Q1 2025.

  • Exome Asset Management reported no remaining Janux Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Exome Asset Management sold 40,123 Janux Therapeutics shares in Q1 2025, an estimated $2.15M.
  • Exome Asset Management first reported a position in Janux Therapeutics in Q4 2024 and held it in 1 quarter.
  • Exome Asset Management's Janux Therapeutics position peaked at $2.15M in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.